Table 2.
Comparison of clinical parameters, lipid levels, metabolic control, and analysis of the concentration of “new biomarkers” of the atherosclerotic process between study groups.
|
DMT1 group with Hashimoto's thyroiditis
N = 20 |
DMT1 group
N = 30 |
Control group
N = 22 |
P-values* | |
|---|---|---|---|---|
| BMI (kg/m2) | 23.3 ± 4.4a, b | 21.28 ± 2.9 | 19.65 ± 2.4 | 0.003 |
| BMI-SDS | 1.015 (0.14–1.36)a, b | 0.24 (−0.2–0.93) | −0.1 (−0.3–0.28) | 0.010 |
| Waist (cm) | 79 ± 10.9a, b | 75.1 ± 7.6 | 69.0 ± 7.4 | <0.001 |
| Waist-SDS | 0.98 (0.52–1.9)a | 0.47 (−0.13–1.18) | −0.14 (−0.27–0.23) | 0.002 |
| SBP (mmHg) | 125 ± 15a | 121.5 ± 11a | 109 ± 9 | <0.001 |
| DBP (mmHg) | 74 ± 8a | 71.1 ± 6 | 69 ± 5 | 0.008 |
| Total cholesterol (mg/dl) | 180 ± 30 | 176 ± 25 | 164 ± 29 | 0.160 |
| LDL (mg/dl) | 96 ± 31 | 101 ± 28 | 89 ± 28 | 0.100 |
| HDL(mg/dl) | 57 ± 10 | 57 ± 11 | 59 ± 11 | 0.150 |
| TG (mg/dl) | 108 ± 354a | 82 ± 27 | 75 ± 39 | 0.005 |
| HbA1c mean % | 8.8 ± 1.4 | 8.1 ± 1.1 | – | 0.040** |
| HbA1c last % | 9.0 ± 1.2a | 8.6 ± 1.1a | 5.4 ± 0.2 | <0.001 |
| Adiponectin (ng/ml) | 8764.3 (6659–14616) | 7704.6 (4816–10231) | 9746.6 (4933–11333) |
0.650 |
| Myeloperoxidase (ng/ml) | 184.6 (120–325)a | 200.8 (95–281)a | 96.8 (72–139) | 0.012 |
| NTproBNP (pg/ml) | 29.5 (17.8–40.0) | 23.4 (15.2–43.8) | 28.9 (17–37) | 0.080 |
| hsCRP (mg/L) | 0.98 (0.4–2.49)a, b | 0.36 (0.23–0.69) | 0.2 (0.1–0.31) | <0.001 |
| Vitamin D (ng/ml) | 17.9 ± 7.9a | 18.5 ± 8.1a | 25.4 ± 5.7 | <0.001 |
The data are presented as mean ± SD or median (interquartile range).
*
ANOVA Kruskal-Wallis test.
**
t-student test.
a
p < 0.05—compared to the control group.
b
p < 0.05—compared to the diabetes group in post-hoc tests.